MSD’s sotatercept has become the first FDA-approved therapy for pulmonary arterial hypertension (PAH) that addresses the underlying mechanism behind the disease, rather than its symptoms. The first-in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback